These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25510513)

  • 21. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Office-based treatment of opioid-dependent patients.
    Ferner RE; Daniels AM
    N Engl J Med; 2003 Jan; 348(1):81-2; author reply 81-2. PubMed ID: 12510051
    [No Abstract]   [Full Text] [Related]  

  • 23. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
    Stinus L; Cador M; Zorrilla EP; Koob GF
    Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical treatment of opioid dependence within the South African context.
    Weich L
    SADJ; 2010 May; 65(4):168-71. PubMed ID: 20632700
    [No Abstract]   [Full Text] [Related]  

  • 25. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of patients with moderately severe methadone dependence onto buprenorphine.
    Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
    Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous use of intranasal naloxone: A case of overdose reversal.
    Das S; Shah N; Ghadiali M
    Subst Abus; 2017; 38(1):18-21. PubMed ID: 27925864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.
    Jones HE; Johnson RE; Jasinski DR; Milio L
    Drug Alcohol Depend; 2005 Apr; 78(1):33-8. PubMed ID: 15769555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.
    Yokell MA; Zaller ND; Green TC; McKenzie M; Rich JD
    J Opioid Manag; 2012; 8(1):63-6. PubMed ID: 22479887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
    Jones HE; Johnson RE; Jasinski DR; O'Grady KE; Chisholm CA; Choo RE; Crocetti M; Dudas R; Harrow C; Huestis MA; Jansson LM; Lantz M; Lester BM; Milio L
    Drug Alcohol Depend; 2005 Jul; 79(1):1-10. PubMed ID: 15943939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.
    Apelt SM; Scherbaum N; Gölz J; Backmund M; Soyka M
    Pharmacopsychiatry; 2013 May; 46(3):94-107. PubMed ID: 23293011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Facilitators and Barriers to Naloxone Kit Use Among Opioid-Dependent Patients Enrolled in Medication Assisted Therapy Clinics in North Carolina.
    Khatiwoda P; Proeschold-Bell RJ; Meade CS; Park LP; Proescholdbell S
    N C Med J; 2018; 79(3):149-155. PubMed ID: 29735615
    [No Abstract]   [Full Text] [Related]  

  • 40. Orexin type 1 receptor antagonism in Lateral Paragigantocellularis nucleus attenuates naloxone precipitated morphine withdrawal symptoms in rats.
    Ahmadi-Soleimani SM; Ghaemi-Jandabi M; Azizi H; Semnanian S
    Neurosci Lett; 2014 Jan; 558():62-6. PubMed ID: 24211689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.